Merck beat Bellus, but their full cough data aren't earning much enthusiasm
It seemed for a few months earlier this year that investors might parse the full Phase III data for Merck’s chronic cough drug like a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
